UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM  i 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i August 10, 2020

Commission File Number:  i 0-24260

 

 

Amedisys, Inc.

(Exact name of registrant as specified in charter)

 

 

i Delaware		i 11-3131700
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

 i 3854 American Way,  i Suite A,  i Baton Rouge,  i LA  i 70816

(Address of principal executive offices, including zip code)

 i (225) 292-2031 or (800)  i 467-2662

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Common Stock, par value $0.001 per share		i AMED		i The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

SECTION 8 – OTHER EVENTS

 

Item 8.01.

Other Events.

On August 10, 2020, Paul B. Kusserow, the President, Chief Executive Officer and Chairman of the Board of Amedisys, Inc. (the “Company”), notified the Company that he is exercising 500,000 of his vested stock options in a “net settled” exercise, pursuant to which the Company will withhold a sufficient number of shares otherwise issuable upon exercise of the options to pay the exercise price of the stock options and the related income tax obligations. Mr. Kusserow will retain the remainder of the shares underlying such exercised stock options and will continue to beneficially own between 1.0% and 1.5% of the Company’s outstanding shares of common stock. These transactions will be reported to the Securities and Exchange Commission in accordance with applicable securities laws, rules and regulations.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.